Embolization for Meningioma
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- St. Olavs Hospital
- Trial code
- NCT05416567
- Record updated
- 21 July 2026
- Original description
The natural course for meningioma suggests that a majority will grow over time. Treatment is usually indicated in growing or symptomatic meningiomas. Surgery is usually primary treatment, but there is a significant risk of adverse effects. Stereotactic radiotherapy is most often reserved to treat relapses after surgery, and except for surgery and radiotherapy there are no other established treatment methods. Endovascular embolization may be used in selected cases as a preoperative adjunct to reduce intraoperative bleeding. There is a need for more treatment options in patients with meningioma, both in uncomplicated, asymptomatic cases and in more complex cases. The aim of this study is to assess radiological and clinical results of therapeutic endovascular embolization for meningiomaRead full original descriptionShow less
Therapeutic Endovascular Embolization for Intracranial Meningioma
The natural course for meningioma suggests that a majority will grow over time. Treatment is usually indicated in growing or symptomatic meningiomas. Surgery is usually primary treatment, but there is a significant risk of adverse effects. Stereotactic radiotherapy is most often reserved to treat relapses after surgery, and except for surgery and radiotherapy there are no other established treatment methods. Endovascular embolization may be used in selected cases as a preoperative adjunct to reduce intraoperative bleeding. There is a need for more treatment options in patients with meningioma, both in uncomplicated, asymptomatic cases and in more complex cases. The aim of this study is to assess radiological and clinical results of therapeutic endovascular embolization for meningioma
Inclusion: Radiological diagnose of typical intracranial meningioma (homogenous contrast enhancement or dural attachment); Indication for treatment due to growth, symptoms or both; Tumor location suggestive of vascular supply via middle meningeal artery branches; Age 18 years or older; Karnofsky performance status of 90 or better (able to carry on normal activity and work).
Exclusion: Previously treated for meningioma; Systemic cancer; Epilepsy; Progressive neurodegenerative disorder (eg. MS, Parkinsons disease); History of psychiatric disorder; Allergic to contrast agents; Informed consent not possible (e.g. language barriers, aphasia, cognitive impaired); Intraosseous growth; Tumor related brain edema; Neurofibromatosis type 2; Unfit for participation for any other reason judged by the physician including patients; Contraindications to MRI; Relative contraindications to endovascular treatment judged from CT angiography (tortoise carotid arteries, carotid stenosis, calcified aortic arch, anatomical vascular variants/anomalies suggesting increased risk with endovascular treatment); DSA (Digital subtraction angiography) from carotid artery suggesting that significant vascular supply is from other vessels than the MMA.